Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015 – Genetic Engineering & Biotechnology News (press release)
FierceBiotech |
Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
Genetic Engineering & Biotechnology News (press release) Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II … Juno ditches lead CAR–T program following patient deaths After Trial Deaths, Juno Pivots and Scraps Lead CAR–T Therapy Months after another lethal setback, Juno finally opts to kill lead CAR–T |
